Trump administration pushes back on opioid meds
Get the Health newsletter
Daily health & science — research, biotech, public health, the studies worth knowing. Free.
- SAMHSA issued a “Dear Colleague” letter in April cautioning against long‑term use of methadone or buprenorphine, stating that medications should not become a default lifelong sentence.
- Michael Stuart, a former West Virginia lawmaker known for sponsoring a ban on methadone treatment, was confirmed in October 2025 as HHS general counsel.
- Rep. Erin Houchin (R‑Ind.) introduced legislation in September that would reinstate daily in‑person methadone clinic visits, require a year of opioid addiction before eligibility, and block telehealth prescribing of methadone or buprenorphine.
- Robert F. Kennedy Jr. publicly affirmed the necessity of Suboxone, methadone, naltrexone, and Narcan at the Rx Summit in April 2025.
- Overdose deaths in the United States have fallen below 70,000 annually for the first time since 2019 after a pandemic‑era peak.
- Addiction experts such as Yngvild Olsen and David Fiellin note that longer treatment duration improves outcomes and that abrupt discontinuation can cause severe withdrawal and relapse.
Why it matters: Patients who rely on evidence‑based opioid medications risk losing access as new restrictions could force daily clinic visits, ban telehealth, and encourage early discontinuation, while addiction providers confront policy shifts that contradict clinical guidelines and may raise overdose risk and mortality.
